The line between pharmaceuticals and nutraceuticals is increasingly merging. At the CPHI 2025 trade show, innovations emerged that blend efficacy and delivery methods from both sectors.
On the showroom floor, Nutrition Insight engaged with PharmaLinea, Lubrizol, Sirio, Corbion, and Bioiberica to explore this convergence and the development of new delivery formats.
Matevž Ambrožič, marketing director at PharmaLinea, emphasized that the pharmaceutical industry is influencing the supplement industry to elevate standards.
“They have substantial marketing power and are applying pressure to the supplement industry to develop higher quality and proof of efficacy.”
PharmaLinea focuses on clinical substantiation as essential in moving toward pharmaceutical-grade supplements. Ambrožič explained that while clinical studies now back many branded ingredients, finished-product clinical validation remains uncommon but is a primary focus for PharmaLinea.
“We already have several product lines clinically studied at the finished-product level, and a large pipeline of upcoming trials. Our goal is to have our entire portfolio clinically substantiated.”
He added that this strategy prepares the company for a future where parts of the supplement industry will likely adhere to pharmaceutical-grade standards.
“That’s our way of adapting to the future that will probably be more pharmaceutical-grade standards — at least for a part of the supplement industry.”
These developments highlight ongoing efforts to raise the credibility and effectiveness of nutraceuticals through rigorous scientific validation.
Author’s summary: The growing overlap between pharmaceuticals and nutraceuticals drives innovation focused on clinical evidence and higher standards to enhance supplement quality and efficacy.
Would you like the HTML styled for web presentation or kept minimal and clean?